Tomorrow at #ESMO26#: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success. 🗓️ Monday, October 26 | 11:15 a.m. CET

Tomorrow at #ESMO26#: MSK sarcoma medical oncologist Dr. Lauren Banks will present research on lifileucel in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. 🗓️ Monday, October 26 | 9:34 a.m. CET

Today at #ESMO26#: Research co-authored by MSK gastrointestinal medical oncologist Dr. Yelena Janjigian will be presented from CLARITY-Gastric 01, a phase 3 study of sonesitatug vedotin in second- or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. 🗓️ Sunday, October 25 | 5:18 p.m. CET

Coming up at #ESMO26#: MSK thoracic surgeon Dr. Daniela Molena will discuss perioperative therapy for locally advanced gastric and gastroesophageal cancer. 🗓️ Sunday, October 25 | 4:30 p.m. CET

Tomorrow at #ESMO26#: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer. 🗓️ Sunday, October 25 | 11:00 a.m. CET

#NEWS#: At #ESMO26#, Amgen presents late-breaking data for our DLL3-targeting T-cell engager, with findings simultaneously published in @NEJM. These landmark results add to our growing body of evidence across the #SCLC# treatment journey. Read more: $AMGN

We just filed our final #ESMO26# newsletter, all stories published. Our work here is done. My partner @DrewQJoseph is an absolute pro. Thanks for all your attention. Much appreciated. And Madrid is wonderful.

About the intismeran presentation at #ESMO26# $MRNA $MRK My impression of discussant talk given by Inge Marie Svane of the University of Copenhagen was that she was positive if not overly enthusiastic about INTerpath-001. "Measured" might be the best, single adjective. "Brutal" is how an investor in the audience described the tone of her talk to me. (He was short Moderna, so there's that.) I disagree. Brutal is too harsh. If people were expecting Svane to jump for joy, then yes, she did not meet that expectation. To me, she played it mostly straight down the middle. She took no position on the mRNA vaccine vs neoadjuvant debate. (Slide below) She noted the lack of intismerna OS benefit, but said the same about neoadjuvant therapy. She also noted greater toxicity associated with neoadjuvant. For intismeran, Svane also raised the question about what exactly was driving the vaccine’s benefit — was it the specific targeting of the neoantigens, or was it the general immune boost that studies have suggested mRNA vaccines generally provide?